drugset / Trial / NCT02367638

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

NCT02367638

Phase 1 Completed 39 enrolled Green Cross Corporation
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to determine whether varicella live vaccine is safe and effective in the healthy adults.

Timeline

Start
2015-03
Primary completion
2015-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject MG1111 Vaccine 0.5 ml Subcutaneous
Comparator Varivax Vaccine Subcutaneous

Indications